Supporting Information for

Novel and Facile Synthesis of 1-Benzazepines via Copper-Catalyzed

Oxidative C(sp³)-H/C(sp²)-H Cross-Coupling

Rui Wang, Ruo-Xing Jin, Zi-Yang Qin, Kang-Jie Bian and Xi-Sheng Wang*

Department of Chemistry, University of Science and Technology of China, 96 Jinzhai Road, Hefei, Anhui 230026, China

*Correspondence to: xswang77@ustc.edu.cn.

Table of Contents


I. General Information
II. Preparation of Substrates
III. Novel and Facile Synthesis of 1-Benzazepines via Copper-
Catalyzed Oxidative C(sp ³)-H/C(sp ²)-H Cross-Coupling
Reaction Optimization DetailsS16
Substrate Screening
IV. Mechanism Details
V. References
VI. Spectroscopic Data (NMR Spectrum)

I. General Information: Instrumentation, Materials.

Instrumentation. ¹H NMR spectra were recorded at ambient temperature on Bruker-400 (400 MHz) spectrometers and are referenced relative to the residual protons in CDCl₃ at δ 7.26 ppm or (CD₃)₂SO-d₆ at δ 2.50 ppm. Data for ¹H NMR are reported as follows: chemical shift (ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, ap = apparent), integration, and coupling constant (Hz). ¹³C NMR spectra were recorded at ambient temperature on Bruker-400 (100 MHz) spectrometers and are referenced relative to CDCl₃ at δ 77.16 ppm or (CD₃)₂SO-d₆ at δ 39.52 ppm. The ¹³C NMR spectra were obtained with 1H decoupling. Data for ¹³C NMR are reported in terms of chemical shift and multiplicity where appropriate. High resolution mass spectra were recorded on P-SIMS-Gly of BrukerDaltonics Inc. using ESI-TOF (electrospray ionization-time of flight). Infrared spectra were determined on a melting point apparatus and are uncorrected.

Materials. Cupric oxide was purchased from Energy Chemical and used as received. Silver acetate was purchased from Beijing HWRK Chem Co., LTD and used as received. Sodium bicarbonate, sodium sulfate and 1,2-dichloroethane were purchased from Sinopharm Chemical Reagent Co., Ltd and used as received. Other commercial reagents were purchased from commercial suppliers and used without further purification.

II. Preparation of Substrates.




Genaral procedure (A) for the synthesis of substrates.

Step 1: Preparation of imines. To an oven-dried round-bottom bottle equipped with a magnetic stir bar was added ketone (1.0 equiv), aniline (1.0 equiv), 4 ÅMS (0.2 g/mmol) and toluene (2.0 M). The mixture was then reflux for 36 h. After completion, it was allowed to cool to room temperature, and was directly filtered through a short pad of Celite[®], washed with EtOAc. The filtrate was concentrated under vacuum and was used directly.


Step 2: Preparation of the substates. Methyllithium (1.6 M in diethyl ether, 3.0 equiv) was added dropwise to a vigorously stirred solution of imine in THF (0.1 M) at -78 °C under N₂ atmosphere and then stirred at 40°C for 1 h (but with **1f** and **1k**, the stirring temperature was 0°C). After completion, the reaction was quenched with water. The resulting aqueous layer was extracted with EtOAc for 3 times and the combined organic layer was washed with brine, dried over Na₂SO₄ and concentrated under vacuum. The crude material was purified by column chromatography on silica gel to give the substrate **1**.

N-(2,5-dimethylhexan-2-yl)aniline (1a)




Prepared according to general procedure (A) from aniline to provide the title compound **1a** as a colorless oil (1.11 g, 5.5 mmol, 55% total yield). IR (neat, cm⁻¹) 3412, 2954, 2929, 2868, 1599, 1496, 1467, 1427, 1383, 1365, 1320, 1258, 1237, 1215, 1179, 1115, 1082, 1031, 995, 867, 743, 691. ¹H NMR (400 MHz, CDCl₃) δ 7.14 (ddd, *J* = 8.1, 6.2, 2.8 Hz, 2H), 6.76 – 6.67 (m, 3H), 3.45 (s, 1H), 1.66 – 1.57 (m, 2H), 1.47 (dq, *J* = 13.1, 6.6 Hz, 1H), 1.28 (s, 6H), 1.26 – 1.18 (m, 2H), 0.86 (d, *J* = 6.6 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 147.1, 129.0, 118.0, 117.0, 53.9, 39.7, 33.2, 28.6, 28.5, 22.8. HRMS (ESI) calcd. for C₁₄H₂₄N [M+H]⁺ *m*/*z* 206.1909, found 206.1908.

N-(2,5-dimethylhexan-2-yl)-4-methylaniline (1b)




Prepared according to general procedure (A) from *p*-toluidine to provide the title compound **1b** as a colorless oil (1.38 g, 6.3 mmol, 63% total yield). IR (neat, cm⁻¹) 2954, 2926, 2867, 1617, 1513, 1467, 1383, 1365, 1304, 1254, 1237, 1182, 1114, 1081, 806. ¹H NMR (400 MHz, CDCl₃) δ 6.96 (d, *J* = 8.1 Hz, 2H), 6.67 (d, *J* = 8.3 Hz, 2H), 2.58 (s, 1H), 2.24 (s, 3H), 1.64 – 1.52 (m, 2H), 1.48 (dt, *J* = 13.2, 6.6 Hz, 1H), 1.27 – 1.19 (m, 8H), 0.87 (d, *J* = 6.6 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 144.4, 129.5, 128.0, 118.5, 54.1, 39.9, 33.3, 28.7, 28.4, 22.9, 20.6. HRMS (ESI) calcd. for C₁₅H₂₆N [M+H]⁺ *m*/z 220.2065, found 220.2069.

N-(2,5-dimethylhexan-2-yl)-4-isopropylaniline (1c)




Prepared according to general procedure (A) from 4-isopropylaniline to provide the title compound **1c** as a yellow oil (0.96 g, 3.9 mmol, 39% total yield). IR (neat, cm⁻¹) 2955, 2929, 2868, 1614, 1514, 1466, 1382, 1364, 1318, 1290, 1255, 1238, 1214, 1185, 1115, 1081, 1055, 818, 727. ¹H NMR (400 MHz, CDCl₃) δ 7.01 (d, *J* = 8.4 Hz, 2H), 6.68 (d, *J* = 8.4 Hz, 2H), 2.80 (dt, *J* = 13.8, 6.9 Hz, 1H), 2.71 (s, 1H), 1.62 – 1.54 (m, 2H), 1.47 (dq, *J* = 13.6, 6.8 Hz, 1H), 1.28 – 1.23 (m, 8H), 1.21 (d, *J* = 6.9 Hz, 6H), 0.87 (d, *J* = 6.6 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 144.7, 138.9, 126.8, 117.9, 54.0, 40.0, 33.3, 33.2, 28.6, 28.4, 24.3, 22.8. HRMS (ESI) calcd. for C₁₇H₃₀N [M+H]⁺ *m/z* 248.2378, found 248.2378.

4-(tert-butyl)-N-(2,5-dimethylhexan-2-yl)aniline (1d)




Prepared according to general procedure (A) from 4-(tert-butyl)aniline to provide the title compound **1d** as a yellow oil (1.02 g, 3.9 mmol, 39% total yield). IR (neat, cm⁻¹) 2954, 2927, 2867, 1614, 1515, 1466, 1383, 1363, 1321, 1305, 1257, 1194, 1113, 1081, 818, 730. ¹H NMR (400 MHz, CDCl₃) δ 7.17 (d, *J* = 8.6 Hz, 2H), 6.69 (d, *J* = 8.6 Hz, 2H), 3.36 (s, 1H), 1.63 – 1.56 (m, 2H), 1.49 (dt, *J* = 13.1, 6.6 Hz, 1H), 1.29 (s, 9H), 1.27 – 1.20 (m, 8H), 0.88 (d, *J* = 6.6 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 144.1, 141.0, 125.6, 117.3, 53.9, 39.8, 33.9, 33.1, 31.6, 28.5, 28.2, 22.7. HRMS (ESI) calcd. for C₁₈H₃₂N [M+H]⁺ *m/z* 262.2535, found 262.2537.

N-(2,5-dimethylhexan-2-yl)-[1,1'-biphenyl]-4-amine (1e)




Prepared according to general procedure (A) from [1,1'-biphenyl]-4-amine to provide the title compound **1e** as a colorless oil (1.35 g, 4.8 mmol, 48% total yield). IR (neat, cm⁻¹) 3413, 2953, 2927, 2867, 1610, 1521, 1486, 1467, 1442, 1383, 1365, 1320, 1299, 1273, 1254, 1237, 1177, 1113, 1076, 822, 759, 695. ¹H NMR (400 MHz, CDCl₃) δ 7.54 (d, *J* = 7.4 Hz, 2H), 7.44 – 7.33 (m, 4H), 7.24 (t, *J* = 7.3 Hz, 1H), 6.77 (d, *J* = 8.5 Hz, 2H), 3.08 (s, 1H), 1.73 – 1.60 (m, 2H), 1.48 (dq, *J* = 12.8, 6.5 Hz, 1H), 1.32 (s, 6H), 1.28 – 1.18 (m, 2H), 0.88 (d, *J* = 6.6 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 146.5, 141.3, 130.4, 128.7, 127.7, 126.4, 126.1, 116.7, 53.9, 39.6, 33.2, 28.6, 28.4, 22.8. HRMS (ESI) calcd. for C₂₀H₂₈N [M+H]⁺ *m/z* 282.2222, found 282.2222.

N-(2,5-dimethylhexan-2-yl)naphthalen-1-amine (1f)




Prepared according to general procedure (A) from naphthalen-1-amine to provide the title compound **1f** as a yellow oil (1.25 g, 4.9 mmol, 49% total yield). IR (neat, cm⁻¹) 3451, 3057, 2953, 2927, 2867, 1578, 1526, 1486, 1463, 1408, 1384, 1365, 1343, 1281, 1225, 1170, 1115, 1099, 1026, 781, 766. ¹H NMR (400 MHz, CDCl₃) δ 7.85 – 7.76 (m, 2H), 7.48 – 7.40 (m, 2H), 7.34 (t, J = 7.9 Hz, 1H), 7.25 (d, J = 8.3 Hz, 1H), 6.92 (d, J = 7.6 Hz, 1H), 4.23 (s, 1H), 1.86 – 1.77 (m, 2H), 1.54 (dt, J = 13.2, 6.6 Hz, 1H), 1.45 (s, 6H), 1.35 – 1.25 (m, 2H), 0.92 (s, 3H), 0.90 (s, 3H).; ¹³C NMR (101 MHz, CDCl₃) δ 141.8, 134.8, 129.0, 126.4, 125.5, 125.0, 124.7, 120.3, 117.4, 108.7, 54.0, 39.5, 33.2, 28.6, 28.2, 22.8. HRMS (ESI) calcd. for C₁₈H₂₆N [M+H]⁺ m/z 256.2065, found 256.2057.

N-(2,5-dimethylhexan-2-yl)-4-fluoroaniline (1g)




Prepared according to general procedure (A) from 4-fluoroaniline to provide the title compound **1g** as a yellow oil (1.12 g, 5.0 mmol, 50% total yield). IR (neat, cm⁻¹) 2955, 2930, 2869, 1613, 1505, 1468, 1384, 1366, 1320, 1212, 1183, 1115, 1101, 818, 786. ¹H NMR (400 MHz, CDCl₃) δ 6.91 – 6.81 (m, 2H), 6.70 (ddd, J = 6.8, 5.3, 3.0 Hz, 2H), 2.75 (s, 1H), 1.58 – 1.51 (m, 2H), 1.47 (dt, J = 13.2, 6.7 Hz, 1H), 1.27 – 1.18 (m, 8H), 0.87 (d, J = 6.6 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 157.1 (d, J = 236.9 Hz), 142.9, 120.0 (d, J = 7.5 Hz), 115.4 (d, J = 22.0 Hz), 54.3, 39.7, 33.2, 28.6, 28.4, 22.8. HRMS (ESI) calcd. for C₁₄H₂₃NF [M+H]⁺ *m/z* 224.1815, found 224.1814.

4-chloro-N-(2,5-dimethylhexan-2-yl)aniline (1h)




Prepared according to general procedure (A) from 4-chloroaniline to provide the title compound **1h** as a colorless oil (1.08 g, 4.5 mmol, 45% total yield). IR (neat, cm⁻¹) 3418, 2954, 2926, 2868, 1727, 1597, 1491, 1467, 1384, 1366, 1319, 1294, 1255, 1237, 1213, 1177, 1093, 813. ¹H NMR (400 MHz, CDCl₃) δ 7.14 – 7.04 (m, 2H), 6.63 (d, *J* = 8.8 Hz, 2H), 3.03 (s, 1H), 1.63 – 1.55 (m, 2H), 1.47 (tt, *J* = 13.1, 6.6 Hz, 1H), 1.27 (s, 6H), 1.24 – 1.14 (m, 2H), 0.86 (d, *J* = 6.6 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 145.6, 128.9, 122.7, 117.9, 54.0, 39.3, 33.2, 28.6, 28.4, 22.8. HRMS (ESI) calcd. for C₁₄H₂₃NCl [M+H]⁺ *m*/*z* 240.1519, found 240.1518.

N-(2,5-dimethylhexan-2-yl)-3-methylaniline (1i)




Prepared according to general procedure (A) from *m*-toluidine to provide the title compound **1i** as a colorless oil (0.99 g, 4.5 mmol, 45% total yield). IR (neat, cm⁻¹) 2953, 2923, 2868, 1712, 1605, 1590, 1515, 1486, 1462, 1378, 1366, 1328, 1262, 1184, 1168, 1082, 1021, 766, 692. ¹H NMR (400 MHz, CDCl₃) δ 7.04 (t, *J* = 7.6 Hz, 1H), 6.61 – 6.49 (m, 3H), 2.87 (s, 1H), 2.27 (s, 3H), 1.65 – 1.58 (m, 2H), 1.49 (dt, *J* = 13.2, 6.6 Hz, 1H), 1.28 (s, 6H), 1.27 – 1.19 (m, 2H), 0.88 (d, *J* = 6.6 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 147.0, 138.7, 128.9, 119.0, 118.0, 114.0, 53.8, 39.8, 33.2, 28.6, 28.4, 22.8, 21.8. HRMS (ESI) calcd. for C₁₅H₂₆N [M+H]⁺ *m*/z 220.2065, found 220.2065.

3-chloro-N-(2,5-dimethylhexan-2-yl)aniline (1j)




Prepared according to general procedure (A) from 3-chloroaniline to provide the title compound **1j** as a colorless oil (1.29 g, 5.4 mmol, 54% total yield). IR (neat, cm⁻¹) 3424, 2955, 2928, 2868, 1593, 1505, 1480, 1384, 1366, 1327, 1237, 1214, 1166, 1096, 1076, 992, 838, 759, 682. ¹H NMR (400 MHz, CDCl₃) δ 7.03 (t, *J* = 8.0 Hz, 1H), 6.72 – 6.61 (m, 2H), 6.55 (dd, *J* = 8.2, 1.7 Hz, 1H), 1.66 – 1.58 (m, 2H), 1.49 (dp, *J* = 13.2, 6.6 Hz, 1H), 1.30 (s, 6H), 1.25 – 1.15 (m, 2H), 0.87 (d, *J* = 6.6 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 148.3, 134.7, 130.0, 117.3, 115.6, 114.2, 53.9, 39.3, 33.1, 28.5, 28.3, 22.8. HRMS (ESI) calcd. for C₁₄H₂₃NCl [M+H]⁺ *m/z* 240.1519, found 240.1520.

N-(2,5-dimethylhexan-2-yl)-3-(trifluoromethyl)aniline (1k)




Prepared according to general procedure (A) from 3-(trifluoromethyl)aniline to provide the title compound **1k** as a yellow oil (0.93 g, 3.4 mmol, 34% total yield). IR (neat, cm⁻¹) 2957, 2871, 1612, 1594, 1522, 1482, 1469, 1433, 1386, 1344, 1317, 1285, 1258, 1217, 1160, 1118, 1098, 1070, 998, 859, 781, 697, 659. ¹H NMR (400 MHz, CDCl₃) δ 7.21 (t, *J* = 7.9 Hz, 1H), 6.95 – 6.86 (m, 2H), 6.83 (d, *J* = 8.2 Hz, 1H), 1.69 – 1.60 (m, 2H), 1.49 (dp, *J* = 13.3, 6.6 Hz, 1H), 1.32 (s, 5H), 1.26 – 1.17 (m, 3H), 0.87 (d, *J* = 6.6 Hz, 5H); ¹³C NMR (101 MHz, CDCl₃) δ 147.3, 131.36 (q, *J* = 31.8 Hz), 129.4, 124.48 (q, *J* = 272.3 Hz), 118.7, 113.75 (q, *J* = 3.8 Hz), 112.10 (q, *J* = 3.8 Hz), 53.9, 39.2, 33.1, 28.5, 28.3, 22.7. HRMS (ESI) calcd. for C₁₅H₂₃NF₃ [M+H]⁺ *m/z* 274.1783, found 274.1780.

N-(2,5-dimethylhexan-2-yl)-3-methoxyaniline (1m)



Prepared according to general procedure (A) from 3-methoxyaniline to provide the title compound **1m** as a yellow oil (0.92 g, 3.9 mmol, 39% total yield). IR (neat, cm⁻¹) 3405, 2953, 2930, 2868, 1610, 1594, 1514, 1492, 1464, 1384, 1366, 1344, 1306, 1265, 1206, 1159, 1116, 1082, 1051, 999, 831, 752, 687. ¹H NMR (400 MHz, CDCl₃) δ 7.08 – 7.00 (m, 1H), 6.35 – 6.24 (m, 3H), 3.77 (s, 3H), 3.12 (s, 1H), 1.70 – 1.57 (m, 2H), 1.47 (tq, *J* = 11.3, 5.7, 4.9 Hz, 1H), 1.29 (s, 6H), 1.26 – 1.18 (m, 2H), 0.87 (d, *J* = 6.6 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 160.5, 148.3, 129.7, 109.7, 102.7, 102.5, 55.2, 53.8, 39.5, 33.2, 28.6, 28.4, 22.8. HRMS (ESI) calcd. for C₁₅H₂₆NO [M+H]⁺ *m/z* 236.2014, found 236.2011.


N-(2,5-dimethylhexan-2-yl)-2-methylaniline (1n)



Prepared according to general procedure (A) from *o*-toluidine to provide the title compound **1n** as a colorless oil (0.22 g, 1.0 mmol, 10% total yield). IR (neat, cm⁻¹) 3444, 2955, 2929, 2868, 1606, 1586, 1514, 1481, 1467, 1443, 1384, 1366, 1318, 1261, 1220, 1177, 1119, 1053, 987, 740, 716. ¹H NMR (400 MHz, CDCl₃) δ 7.10 – 7.02 (m, 2H), 6.86 (d, *J* = 7.9 Hz, 1H), 6.63 (t, *J* = 7.3 Hz, 1H), 3.01 (s, 1H), 2.13 (s, 3H), 1.75 – 1.63 (m, 2H), 1.49 (dp, *J* = 12.9, 6.5 Hz, 1H), 1.34 (s, 6H), 1.26 – 1.15 (m, 2H), 0.87 (d, *J* = 6.6 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ


145.1, 130.5, 126.7, 123.2, 116.7, 113.6, 53.59, 39.6, 33.2, 28.6, 28.5, 22.8, 18.3. HRMS (ESI) calcd. for $C_{15}H_{26}N [M+H]^+ m/z$ 220.2065, found 220.2065.

N-(1-isopentylcyclohexyl)aniline (1t)




Prepared according to general procedure (A) from cyclohexanone and aniline to provide the title compound **1t** as a colorless oil (1.32 g, 5.4 mmol, 54% total yield). IR (neat, cm⁻¹) 3425, 2926, 2854, 1599, 1496, 1462, 1428, 1383, 1365, 1320, 1279, 1253, 1172, 1120, 1080, 1041, 998, 925, 898, 865, 743, 690. ¹H NMR (400 MHz, CDCl₃) δ 7.21 – 7.04 (m, 2H), 6.77 – 6.59 (m, 3H), 3.26 (s, 1H), 1.77 – 1.97 (m, 2H), 1.72 – 1.61 (m, 2H), 1.61 – 1.25 (m, 9H), 1.25 – 1.13 (m, 2H), 0.84 (d, *J* = 6.6 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 147.0, 129.0, 117.3, 116.1, 55.4, 36.8, 36.4, 32.0, 28.5, 26.2, 22.8, 22.0. HRMS (ESI) calcd. for C₁₇H₂₈N [M+H]⁺ *m/z* 246.2222, found 246.2221.

N-(2-methylhexan-2-yl)aniline (1u)




Prepared according to general procedure (A) from hexan-2-one and aniline to provide the title compound **1u** as a colorless oil (0.96 g, 5.0 mmol, 50% total yield). IR (neat, cm⁻¹) 3413, 2957, 2930, 2860, 1600, 1496, 1467, 1427, 1383, 1365, 1321, 1258, 1234, 1215, 1178, 1098, 1080, 1031, 995, 867, 805, 744, 691. ¹H NMR (400 MHz, CDCl₃) δ 7.14 (ddd, *J* = 8.1, 6.2, 2.8 Hz, 2H), 6.76 – 6.67 (m, 3H), 3.45 (s, 1H), 1.66 – 1.57 (m, 2H), 1.47 (dq, *J* = 13.1, 6.6 Hz, 1H), 1.28 (s, 6H), 1.26 – 1.18 (m, 2H), 0.86 (d, *J* = 6.6 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 147.1, 129.0, 118.0, 117.0, 53.9, 39.7, 33.2, 28.6, 28.5, 22.8. HRMS (ESI) calcd. for C₁₃H₂₂N [M+H]⁺ *m/z* 192.1752, found 192.1752.

N-(2,5-dimethylhexan-2-yl)-9,9-diphenyl-9H-fluoren-2-amine (1ab)



Prepared according to general procedure (A) from 9,9-diphenyl-9H-fluoren-2-amine to provide the title compound **1ab** as a off-white solid (2.49 g, 5.6 mmol, 56% total yield). m.p.: 135 – 137 °C. IR (neat, cm⁻¹) 3416, 2957, 2860, 1610, 1582, 1519, 1490, 1458, 1413, 1383, 1351, 1321, 1292, 1235, 1216, 1163, 1117, 1098, 1079, 1030, 851, 813, 781, 756, 726, 697, 657, 635,

620, 599, 552, 479, 440. ¹H NMR (400 MHz, CDCl₃) δ 7.60 (d, J = 7.5 Hz, 1H), 7.53 (d, J = 8.2 Hz, 1H), 7.34 (d, J = 7.6 Hz, 1H), 7.31 – 7.26 (m, 1H), 7.25 – 7.16 (m, 10H), 7.17 – 7.11 (m, 1H), 6.75 (d, J = 2.0 Hz, 1H), 6.71 (dd, J = 8.2, 2.1 Hz, 1H), 1.61 – 1.51 (m, 2H), 1.39 (dp, J = 13.2, 6.6 Hz, 1H), 1.24 (s, 6H), 1.20 – 1.12 (m, 2H), 0.80 (d, J = 6.6 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 152.6, 150.4, 147.1, 146.6, 141.0, 130.5, 128.4, 128.2, 127.4, 126.5, 126.0, 125.9, 120.7, 118.9, 116.6, 114.4, 65.5, 54.1, 39.1, 33.2, 28.6, 28.5, 22.8. HRMS (ESI) calcd. for C₃₃H₃₆N [M+H]⁺ m/z 446.2848, found 446.2848.




Genaral procedure (B) for the synthesis of substrates.

Step 1: Preparation of imines. The imines were prepared according to Step 1 of general procedure (A).

Step 2: Preparation of lithium reagents. The bromide (4.0 equiv) in Et₂O (4.0 M) was added dropwise to a vigorously stirred suspension of lithium rods (10.0 equiv) in Et₂O (4.0 M) at - 40 °C under N₂ atmosphere. And the mixture was allowed to warm up to 5 °C and stirred for 2 h. The resulting blackish suspension was then used imediately.


Step 3: Preparation of the substates. The freshly prepared lithium reagent was added dropwise to a vigorously stirred solution of imine in THF (0.1 M) at -78 °C under N₂ atmosphere and then stirred at 40°C for 1 h. After completion, the reaction was quenched with water. The resulting aqueous layer was extracted with EtOAc for 3 times and the combined organic layer was washed with brine, dried over Na₂SO₄ and concentrated under vacuum. The crude material was purified by column chromatography on silica gel to give the substrate **1**.

N-(3,6-dimethylheptan-3-yl)aniline (10)




Prepared according to general procedure (B) from bromoethane to provide the title compound **10** as a colorless oil (0.99 g, 4.5 mmol, 45% total yield). IR (neat, cm⁻¹) 3416, 2955, 2932, 2869, 1599, 1496, 1464, 1429, 1378, 1366, 1320, 1255, 1203, 1177, 1115, 1081, 1032, 994, 867, 743, 691. ¹H NMR (400 MHz, CDCl₃) δ 7.14 (t, *J* = 7.9 Hz, 2H), 6.75 – 6.66 (m, 3H), 3.25 (s, 1H), 1.78 – 1.42 (m, 5H), 1.25 – 1.15 (m, 5H), 0.93 – 0.83 (m, 9H); ¹³C NMR (101 MHz, CDCl₃) δ 147.1, 129.0, 117.5, 116.3, 56.3, 37.2, 32.7, 32.0, 28.6, 25.7, 22.8, 8.2. HRMS (ESI) calcd. for C₁₅H₂₆N [M+H]⁺ *m/z* 220.2065, found 220.2065.

N-(4,7-dimethyloctan-4-yl)aniline (1p)




Prepared according to general procedure (B) from 1-bromopropane to provide the title compound **1p** as a colorless oil (0.96 g, 4.1 mmol, 41% total yield). IR (neat, cm⁻¹) 3416, 2954, 2931, 2869, 1599, 1496, 1467, 1428, 1377, 1366, 1323, 1251, 1177, 1117, 1080, 1033, 994, 866, 743, 691. ¹H NMR (400 MHz, CDCl₃) δ 7.17 – 7.08 (m, 2H), 6.73 – 6.64 (m, 3H), 1.69 – 1.50 (m, 4H), 1.46 (dq, *J* = 13.2, 6.6 Hz, 1H), 1.34 (ddd, *J* = 11.6, 9.4, 5.4 Hz, 2H), 1.23 (s, 3H), 1.21 – 1.12 (m, 2H), 0.94 – 0.80 (m, 9H); ¹³C NMR (101 MHz, CDCl₃) δ 147.1, 129.0, 117.5, 116.3, 56.2, 42.4, 37.6, 32.8, 28.6, 26.3, 22.8, 17.0, 14.8. HRMS (ESI) calcd. for C₁₆H₂₈N [M+H]⁺ *m/z* 234.2222, found 234.2222.

N-(2,5-dimethylnonan-5-yl)aniline (1q)



Prepared according to general procedure (B) from 1-bromobutane to provide the title compound **1q** as a colorless oil (1.06 g, 4.3 mmol, 43% total yield). IR (neat, cm⁻¹) 2954, 2929, 2868, 1600, 1497, 1467, 1377, 1323, 1256, 1178, 1080, 1034, 994, 866, 743, 691. ¹H NMR (400 MHz, CDCl₃) δ 7.18 – 7.08 (m, 2H), 6.73 – 6.65 (m, 3H), 3.17 (s, 1H), 1.69 – 1.51 (m, 4H), 1.47 (dt, J = 13.2, 6.6 Hz, 1H), 1.34 – 1.26 (m, 4H), 1.26 – 1.15 (m, 5H), 0.92 – 0.82 (m, 9H); ¹³C NMR (101 MHz, CDCl₃) δ 147.1, 129.0, 117.5, 116.3, 56.1, 39.6, 37.5, 32.8, 28.6, 26.2, 26.0, 23.3, 22.8, 14.3. HRMS (ESI) calcd. for C₁₇H₃₀N [M+H]⁺ m/z 248.2378, found 248.2379.


N-(2,3,6-trimethylheptan-3-yl)aniline (1r)




Prepared according to general procedure (B) from 3-methylbutan-2-one and 1-bromo-3-

methylbutane to provide the title compound **1r** as a colorless oil (0.54 g, 2.3 mmol, 23% total yield). IR (neat, cm⁻¹) 3417, 2954, 2870, 1599, 1496, 1467, 1430, 1387, 1366, 1311, 1256, 1230, 1173, 1101, 1033, 994, 867, 744, 690. ¹H NMR (400 MHz, CDCl₃) δ 7.18 – 7.08 (m, 2H), 6.72 – 6.63 (m, 3H), 3.45 (s, 1H), 2.18 (p, *J* = 6.8 Hz, 1H), 1.79 – 1.67 (m, 1H), 1.66 – 1.54 (m, 1H), 1.46 (dh, *J* = 13.2, 6.6 Hz, 1H), 1.30 – 1.18 (m, 2H), 1.14 (s, 3H), 1.01 – 0.77 (m, 12H); ¹³C NMR (101 MHz, CDCl₃) δ 147.2, 129.1, 117.2, 116.0, 58.8, 35.1, 34.5, 32.6, 28.7, 22.9, 22.8, 21.8, 17.8, 17.3. HRMS (ESI) calcd. for C₁₆H₂₈N [M+H]⁺ *m/z* 234.2222, found 234.2222.

N-(2,5,8-trimethylnonan-5-yl)aniline (1s)



Prepared according to general procedure (B) from 1-bromo-3-methylbutane to provide the title compound **1s** as a colorless oil (1.10 g, 4.2 mmol, 42% total yield). IR (neat, cm⁻¹) 2952, 2929, 2868, 1600, 1497, 1467, 1428, 1377, 1366, 1322, 1271, 1256, 1172, 1105, 1080, 1040, 995, 866, 743, 691. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.18 – 7.09 (m, 2H), 6.73 – 6.65 (m, 3H), 3.03 (s, 1H), 1.70 – 1.51 (m, 4H), 1.46 (dq, *J* = 13.2, 6.6 Hz, 2H), 1.27 – 1.14 (m, 7H), 0.87 (dd, *J* = 6.6, 2.2 Hz, 12H); ¹³C NMR (101 MHz, CDCl₃) δ 147.1, 129.0, 117.5, 116.4, 56.1, 37.5, 32.8, 28.6, 26.3, 22.8. HRMS (ESI) calcd. for C₁₈H₃₂N [M+H]⁺ *m*/*z* 262.2535, found 262.2537.




Genaral procedure (C) for the synthesis of substrates.

Step 1: Preparation of Diphenylamines. The diphenylamines were prepared according to a method developed by Barros *et al.*^[1] A solution of 2-cyclohexenone, amine, iodine and *p*-TsOH in DMSO was heated at 90 °C for 1 h. After completion, the reaction was cooled to rt and DCM was added. The solution was washed with 20% Na₂S₂O₃ followed by brine. The organic layer was dried over Na₂SO₄ and concentrated under vacuum. The crude was purified by column chromatography on silica gel to give the diphenylamine.

Step 2: Preparation of the substates. To a mixture of diphenylamine, isobutylboronic acid , K_3PO_4 and PCy_3 in toluene/H₂O was added Pd(OAc)₂ under N₂. The reaction was then heated


at 100 °C for 30 h. After completion, it was allowed to cool to rt and washed with water. The aqueous layer was extracted with EtOAc for 3 times and the combined organic layer was washed with brine, dried over Na_2SO_4 . After concentrated under vaccum, the crude material was purified by column chromatography on silica gel to provide the substrate **1**.

2-isobutyl-N-phenylaniline (1v)




Prepared according to general procedure (C) from 2-bromoaniline to provide the title compound **1v** as a yellow oil (1.53 g, 6.8 mmol, 68% total yield). IR (neat, cm⁻¹) 3390, 2953, 2924, 2866, 1594, 1579, 1496, 1456, 1415, 1383, 1365, 1297, 1174, 1123, 1078, 1027, 995, 890, 812, 743, 692. ¹H NMR (400 MHz, CDCl₃) δ 7.33 – 7.24 (m, 3H), 7.22 – 7.14 (m, 2H), 7.00 (td, *J* = 7.5, 1.2 Hz, 1H), 6.99 – 6.94 (m, 2H), 6.91 (t, *J* = 7.3 Hz, 1H), 5.44 (s, 1H), 2.52 (d, *J* = 7.2 Hz, 2H), 1.96 (dp, *J* = 13.6, 6.7 Hz, 1H), 0.98 (d, *J* = 6.6 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 144.7, 141.0, 132.6, 131.3, 129.4, 126.8, 122.3, 120.4, 120.2, 117.1, 41.0, 28.9, 22.8. HRMS (ESI) calcd. for C₁₆H₂₀N [M+H]⁺ *m/z* 226.1596, found 226.1601.

2-isobutyl-4-methyl-N-phenylaniline (1w)



Prepared according to general procedure (C) from 2-bromo-4-methylaniline to provide the title compound **1w** as a yellow oil (1.36 g, 5.7 mmol, 57% total yield). IR (neat, cm⁻¹) 3389, 2952, 2922, 2866, 1597, 1495, 1463, 1407, 1382, 1365, 1307, 1226, 1176, 1128, 1077, 1027, 994, 887, 804, 744, 691. ¹H NMR (400 MHz, CDCl₃) δ 7.28 – 7.18 (m, 3H), 7.06 – 6.99 (m, 2H), 6.92 – 6.83 (m, 3H), 5.33 (s, 1H), 2.49 (d, *J* = 7.2 Hz, 2H), 2.36 (s, 3H), 1.93 (hept, *J* = 6.8 Hz, 1H), 0.97 (d, *J* = 6.6 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 145.7, 138.1, 134.1, 132.5, 131.9, 129.3, 127.4, 122.3, 119.4, 116.0, 40.9, 29.2, 22.8, 21.0. HRMS (ESI) calcd. for C₁₇H₂₂N [M+H]⁺ *m/z* 240.1752, found 240.1757.


4-chloro-2-isobutyl-N-phenylaniline (1x)



Prepared according to general procedure (C) from 2-bromo-4-chloroaniline to provide the title compound **1x** as a colorless oil (1.94 g, 7.5 mmol, 75% total yield). IR (neat, cm⁻¹) 3381, 2957, 2923, 2866, 1593, 1508, 1487, 1434, 1383, 1362, 1337, 1276, 1258, 1209, 1165, 1131, 1115,


1087, 1053, 978, 933, 904, 812, 748, 693. ¹H NMR (400 MHz, CDCl₃) δ 7.36 (t, *J* = 7.9 Hz, 2H), 7.31 – 7.24 (m, 2H), 7.20 (dd, *J* = 8.5, 2.4 Hz, 1H), 7.07 – 6.99 (m, 3H), 5.45 (s, 1H), 2.56 (d, *J* = 7.3 Hz, 2H), 2.03 (dp, *J* = 13.7, 7.0 Hz, 1H), 1.06 (d, *J* = 6.6 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 144.2, 139.7, 134.4, 130.8, 129.5, 127.0, 126.8, 121.5, 120.7, 117.3, 40.7, 28.8, 22.7. HRMS (ESI) calcd. for C₁₆H₁₉NCl [M+H]⁺ *m/z* 260.1206, found 260.1208.

5-chloro-2-isobutyl-N-phenylaniline (1y)




Prepared according to general procedure (C) from 2-bromo-5-chloroaniline to provide the title compound **1y** as a yellow oil (1.86 g, 7.2 mmol, 72% total yield). IR (neat, cm⁻¹) 3425, 2953, 2924, 2867, 1590, 1572, 1496, 1475, 1405, 1384, 1366, 1308, 1269, 1176, 1129, 1077, 1027, 923, 863, 827, 787, 747, 692, 667. ¹H NMR (400 MHz, CDCl₃) δ 7.35 – 7.28 (m, 2H), 7.24 (d, J = 2.1 Hz, 1H), 7.07 (d, J = 8.1 Hz, 1H), 7.00 (dd, J = 16.5, 7.9 Hz, 3H), 6.90 (dd, J = 8.1, 2.1 Hz, 1H), 5.45 (s, 1H), 2.46 (d, J = 7.3 Hz, 2H), 1.93 (hept, J = 6.8 Hz, 1H), 0.97 (d, J = 6.6 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 143.1, 142.6, 132.2, 132.1, 129.6, 129.3, 121.6, 121.3, 118.6, 118.2, 40.5, 28.6, 22.7. HRMS (ESI) calcd. for C₁₆H₁₉NCl [M+H]⁺ *m/z* 260.1206, found 260.1210.

5-fluoro-2-isobutyl-N-phenylaniline (1z)




Prepared according to general procedure (C) from 2-bromo-5-fluoroaniline to provide the title compound **1z** as a colorless oil (1.87 g, 7.7 mmol, 77% total yield). IR (neat, cm⁻¹) 3437, 2954, 2925, 2867, 1595, 1512, 1496, 1464, 1430, 1417, 1384, 1366, 1310, 1278, 1240, 1157, 1109, 1078, 1027, 986, 850, 787, 742, 692. ¹H NMR (400 MHz, CDCl₃) δ 7.37 – 7.28 (m, 2H), 7.13 – 7.03 (m, 3H), 7.03 – 6.94 (m, 2H), 6.63 (td, *J* = 8.3, 2.6 Hz, 1H), 5.52 (s, 1H), 2.47 (d, *J* = 7.3 Hz, 2H), 1.93 (hept, *J* = 6.8 Hz, 1H), 0.98 (d, *J* = 6.6 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 162.0 (d, *J* = 242.3 Hz), 143.0, 142.9 (d, *J* = 10.1 Hz), 132.1 (d, *J* = 9.4 Hz), 129.6, 126.0, 125.9, 121.7, 118.8, 107.6 (d, *J* = 21.1 Hz), 104.7 (d, *J* = 24.7 Hz), 40.4, 28.7, 22.7. HRMS (ESI) calcd. for C₁₆H₁₉NF [M+H]⁺ *m*/z 244.1502, found 244.1508.

2-isobutyl-N-phenyl-5-(trifluoromethyl)aniline (1aa)



Prepared according to general procedure (C) from 2-bromo-5-(trifluoromethyl)aniline to provide the title compound **1aa** as a colorless oil (2.73 g, 8.1 mmol, 81% total yield). IR (neat, cm⁻¹) 3440, 2957, 2870, 1598, 1582, 1520, 1497, 1467, 1431, 1419, 1329, 1271, 1222, 1162, 1115, 1073, 933, 878, 835, 804, 744, 693. ¹H NMR (400 MHz, CDCl₃) δ 7.51 (s, 1H), 7.36 – 7.29 (m, 2H), 7.26 (d, *J* = 7.9 Hz, 1H), 7.19 (d, *J* = 7.9 Hz, 1H), 7.02 (dd, *J* = 11.7, 7.6 Hz, 3H), 5.54 (s, 1H), 2.55 (d, *J* = 7.3 Hz, 2H), 1.99 (dp, *J* = 13.6, 6.7 Hz, 1H), 1.00 (d, *J* = 6.6 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 143.1, 141.9, 134.8, 131.6, 129.7, 129.3 (q, *J* = 32.2 Hz), 124.4 (q, *J* = 272.1 Hz), 121.7, 118.5, 117.9 (q, *J* = 3.8 Hz), 115.0 (q, *J* = 3.8 Hz), 40.9, 28.6, 22.8. HRMS (ESI) calcd. for C₁₇H₁₉NF₃ [M+H]⁺ *m*/z 294.1470, found 294.1481.

3-((2,5-dimethylhexan-2-yl)amino)benzonitrile (11)




Step 1: Preparation of 2,5-dimethylhexan-2-amine. Ceric ammonium nitrate (2.5 equiv) in MeCN (0.1 M) was added to a solution of N-(2,5-dimethylhexan-2-yl)-4-methoxyaniline (1.0 equiv) in MeCN (0.05 M) dropwise at 0 °C and stirred at rt for 1 h. After completion, water and Et₂O were added, the layers were separated and the aqueous layer was washed with Et₂O. The aqueous layer was basified with sodium carbonate to pH 10 and extracted with Et₂O. The combined organic layer was then acidized with 2N HCl and washed with water. The combined aqueous layer was again basified with sodium carbonate to pH 10 and extracted with Et₂O and the combined organic layer was dried over Na₂SO₄ and concentrated to give the 2,5-dimethylhexan-2-amine as a light yellow oil (2.45 g, 19.0 mmol, 19%).

Step 2: Preparation of 3-((2,5-dimethylhexan-2-yl)amino)benzonitrile (11). 11 was prepared according to the method developped by Beller *et al*^[2]. To a 25 mL pressure tube was added $Pd(OAc)_2$ (0.005 equiv), di(1-adamantyl)-*N*-butylphosphine hydroiodide (0.01 equiv), and NaOtBu (1.2 equiv) and was purged with argon. Toluene (1.0 M), 3-chlorobenzonitrile (1.0 equiv) and 2,5-dimethylhexan-2-amine (1.2 equiv) were added successively. The mixture was stirred at 120 °C for 20 h. After cooling to rt, the mixture was diluted with diethyl ether and washed with water. The organic phase was dried over Na₂SO₄ and concentrated. The crude was purified by column chromatography on silica gel to provide 11 as a colorless oil (0.23 g, 1.0 mmol, 50%). IR (neat, cm⁻¹) 3391, 2955, 2930, 2868, 2227, 1599, 1581, 1519, 1483, 1467,

1421, 1385, 1367, 1338, 1303, 1238, 1217, 1174, 1116, 1079, 1004, 850, 777, 683. ¹H NMR (400 MHz, CDCl₃) δ 7.17 (t, *J* = 7.9 Hz, 1H), 6.92 (d, *J* = 7.4 Hz, 1H), 6.89 (s, 1H), 6.83 (d, *J* = 8.3 Hz, 1H), 3.73 (s, 1H), 1.70 – 1.55 (m, 2H), 1.53 – 1.40 (m, 1H), 1.31 (s, 6H), 1.23 – 1.11 (m, 2H), 0.86 (s, 3H), 0.85 (s, 3H).; ¹³C NMR (101 MHz, CDCl₃) δ 147.4, 129.8, 120.6, 120.0, 119.7, 117.6, 112.8, 53.9, 39.0, 33.1, 28. 5, 28.2, 22.8. HRMS (ESI) calcd. for C₁₅H₂₃N₂ [M+H]⁺ *m/z* 231.1861, found 231.1854.

III. Novel and Facile Synthesis of 1-Benzazepines via Copper-Catalyzed Oxidative C(sp³)-H/C(sp²)-H Cross-Coupling Reaction Optimization

Table S1 | Solvent Screening




1a



entry	Solvent	yield ^a	entry	Solvent	yield ^a
1	DCE	19 (20 ^b)	2	PhCH ₃	6
3	PhCF ₃	19	4	<i>m</i> -xylene	0
5	o-xylene	0	6	mesitylene	0
7	<i>p</i> -xylene	0	8	CH_2CI_2	13
9	PhCl	0	10	1,1,2,2-TeCE	0
11	CHCI ₃	3	12	DMSO	0
13	1,1,1-TrCE	3	14	1,4-dioxane	13
15	DMF	2	16	MeCN	14
17	THF	8	18	PrOH	3
19	Acetone	11	20	PE	25
21	MeNO ₂	1	22	1-Bromobutane	4
23	MeOH	2	24	DME	22
25	1,2-DBE	0	26	<i>i</i> -PrOH	11
27	MTBE	9	28	ME	0
29	EA	3	30	<i>i</i> -BuOH	7
31	EtOH	6	32	<i>t</i> -BuOH	21
33	BuOH	2	34	TFE	0
35	<i>t</i> -AmOH	13	36	HFIP	0

^aDetermined by GC.^bIsolated yield.


Table S2 | Oxidant Screening



entry	Oxidant (equiv)	yield ^a	entry	Oxidant (equiv)	yield ^a
1	K ₂ S ₂ O ₈ (2.0)	0	2	TEMPO (4.0)	0
3	BPO (2.0)	0	4	PIDA (2.0)	0
5	AgOAc (4.0)	7	6	<i>t</i> -BuOOH (2.0)	0
7	O ₂ (1 atm)	0	8	<i>t</i> -BuOO <i>t</i> -Bu (2.0)	6
9	Oxone (2.0)	0	10	NFSI (2.0)	0
11	AgNO ₃ (4.0)	0	12	BQ (2.0)	0
13	DDQ (2.0)	0	14	AgTFA (4.0)	0
15	PivOAg (4.0)	0	16	<i>n</i> -C ₆ H ₁₁ COOAg (4	.0) 0
17	AgOTf (4.0)	0	18	Ag ₂ O (2.0)	48
19	AgF (4.0)	0	20	AgOTs (4.0)	0
21	AgClO ₄ (4.0)	0	22	AgNO ₂ (4.0)	0
23	AgMes (4.0)	0	24	(NH ₄) ₂ S ₂ O ₈ (2.0)	0
25	Na ₂ S ₂ O ₈ (2.0)	0	26	Ce(SO ₄) ₂ (4.0)	0
27	CAN (4.0)	0	28	FeCl ₃ (4.0)	0
29	FeBr ₃ (4.0)	0	30	FeF ₃ (4.0)	0
31	Fe(NO ₃) ₃ (4.0)	0	32	Fe ₂ (SO ₄) ₃ (4.0)	0
33	Cu(OAc) ₂ (4.0)	0	34	AgOAc (4.0) Na ₂ CO ₃ (4.0)	44

^aDetermined by GC.

Table S3 | Ag salts Screening



^aDetermined by GC.

Table S4 | Base Screening

H N AgOAc (4.0 equiv), base (n equiv)						$\left\{ \right.$
$\overline{\mathcal{A}}$]	•	0.05 M) C, 30 h			_
1a					2a	
entry	base (equiv)	yield ^a	entry	base (equiv)	yield ^a	
1	Na ₂ CO ₃ (2.0)	61	2	Li ₂ CO ₃ (2.0)	20	
3	K ₂ CO ₃ (2.0)	41	4	Cs ₂ CO ₃ (2.0)	46	
5	NaHCO ₃ (4.0)	57	6	KHCO ₃ (4.0)	55	
7	K ₃ PO ₄ (1.3)	43	8	KF (4.0)	53	

^aDetermined by GC.

Table S5 | Cu salts Screening

	AgOAc (4.0		n mol%) Na ₂ CO ₃	(2.0 equiv)	H N	
			DCE (0.05 M) 135 °C, 24 h			
1	а				2a	
entry	[Cu] (n mol%)	yield ^a	entry	[Cu] (n mol%)	yield ^a	
1	Cu (20)	54	2	Cu ₂ O (10)	34	
3	Cu ₂ (OH) ₂ CO ₃ (10)	61	4	CuCO ₃ (20)	61	
5	CuCN (20)	62	6	CuO (20)	70	

^aDetermined by GC.

Table S6 | Re-screening of Base

× N→	AgOAc (4	CuO (20 .0 equiv	,	(n equiv)	¥ ^H N−	f
\mathcal{A}	/	DCE (0 135 °C]
1a					2a	
entry	base (equiv)	yield ^a	entry	base (equiv)	yield ^a	
1	Na ₂ CO ₃ (2.0)	77	2	Li ₂ CO ₃ (2.0)	52	
3	K ₂ CO ₃ (2.0)	71	4	Cs ₂ CO ₃ (2.0)	45	
5	NaHCO ₃ (4.0)	85	6	KHCO ₃ (4.0)	74	
7	K ₃ PO ₄ (1.3)	50	8	KF (4.0)	71	
9	NaOAc (4.0)	61				

^aDetermined by GC.





Table S7 | Variation of Standard Conditions

^alsolated yield.

Substrate Screening




Genaral procedure (D) for the novel and facile synthesis of 1-benzazepines via coppercatalyzed oxidative $C(sp^3)$ -H/C(sp²)-H cross-coupling. To an oven-dried 35 mL screw-cap sealed tube equipped with a magnetic stir bar was added CuO (20 mol%), AgOAc (4.0 equiv), NaHCO₃ (4.0 equiv), Na₂SO₄ (2.0 equiv), substrate **1** (0.3 mmol, 1.0 equiv) and 1,2dichloroethane (6.0 mL) at air atmosphere. The vessel was then sealed with a Teflon screw-cap, stirred vigorously at rt for 5 min, and placed into a preheated oil bath at 125 °C for 30 h. After completion, the reaction mixture was allowed to cool to room temperature, and was directly filtered through a short pad of silica gel washed with EtOAc. The filtrate was concentrated under vacuum and purified by column chromatography on silica gel to obtain the corresponding product **2**.

2,2,5,5-tetramethyl-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepine (2a)



Prepared according to general procedure (D) using **1a** to provide the title compound **2a** as a colorless oil (56.6 mg, 0.28 mmol, 93%). IR (neat, cm⁻¹) 2953, 2921, 2852, 1738, 1460, 1377, 1362, 1260, 1237, 1162, 1083, 1053, 1020, 972, 851, 802, 751. ¹H NMR (400 MHz, CDCl₃) δ 7.27 (d, *J* = 7.1 Hz, 1H), 7.01 (td, *J* = 7.5, 1.3 Hz, 1H), 6.93 – 6.87 (m, 1H), 6.61 (d, *J* = 7.6 Hz, 1H), 2.74 (s, 1H), 1.83 – 1.69 (m, 2H), 1.69 – 1.60 (m, 2H), 1.37 (s, 4H), 1.12 (s, 4H); ¹³C NMR (101 MHz, CDCl₃) δ 146.1, 140.0, 126.5, 126.5, 123.1, 121.5, 52.7, 38.2, 38.1, 36.6, 29.4. HRMS (ESI) calcd. for C₁₄H₂₂N [M+H]⁺ *m/z* 204.1752, found 204.1757.


2,2,5,5,7-pentamethyl-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepine (2b)



Prepared according to general procedure (D) using **1b** to provide the title compound **2b** as a colorless oil (50.1 mg, 0.23 mmol, 77%). IR (neat, cm⁻¹) 2957, 2923, 2854, 1737, 1606, 1479, 1467, 1443, 1382, 1360, 1259, 1241, 1193, 1177, 1162, 1145, 1088, 1020, 806, 675. ¹H NMR (400 MHz, CDCl₃) δ 7.06 (s, 1H), 6.81 (d, *J* = 7.6 Hz, 1H), 6.51 (d, *J* = 7.7 Hz, 1H), 2.27 (s, 3H), 1.80 – 1.67 (m, 2H), 1.67 – 1.58 (m, 2H), 1.36 (s, 6H), 1.10 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 143.5, 139.9, 130.5, 127.4, 126.9, 123.1, 52.6, 38.2, 38.0, 36.7, 29.0, 21.1. HRMS


(ESI) calcd. for $C_{15}H_{24}N [M+H]^+ m/z 218.1909$, found 218.1912.

7-isopropyl-2,2,5,5-tetramethyl-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepine (2c)




Prepared according to general procedure (D) (but for 25 h.) using **1c** to provide the title compound **2c** as a colorless oil (47.8 mg, 0.20 mmol, 65%). IR (neat, cm⁻¹) 2955, 2927, 2866, 1607, 1504, 1478, 1440, 1383, 1361, 1322, 1269, 1241, 1194, 1177, 1165, 1150, 1103, 1087, 1059, 1019, 945, 910, 887, 823, 775, 736, 690, 667, 639. ¹H NMR (400 MHz, CDCl₃) δ 7.09 (d, *J* = 2.0 Hz, 1H), 6.85 (dd, *J* = 7.9, 2.0 Hz, 1H), 6.53 (d, *J* = 7.8 Hz, 1H), 2.83 (hept, *J* = 6.9 Hz, 1H), 1.83 – 1.67 (m, 2H), 1.67 – 1.57 (m, 2H), 1.37 (s, 6H), 1.22 (d, *J* = 6.9 Hz, 3H), 1.09 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 143.7, 141.7, 139.8, 125.0, 123.8, 122.9, 52.6, 38.3, 38.2, 36.8, 33.7, 29.3, 24.4. HRMS (ESI) calcd. for C₁₇H₂₈N [M+H]⁺ *m/z* 246.2222, found 246.2232.

7-(tert-butyl)-2,2,5,5-tetramethyl-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepine (2d)



Prepared according to general procedure (D) (but with 3 equiv [Ag].) using **1d** to provide the title compound **2d** as a colorless oil (66.0 mg, 0.26 mmol, 85%). IR (neat, cm⁻¹) 2955, 2865, 1606, 1504, 1478, 1440, 1384, 1360, 1268, 1244, 1195, 1177, 1166, 1150, 1088, 1018, 945, 887, 820, 770, 745, 687, 656, 642, 553, 504. ¹H NMR (400 MHz, CDCl₃) δ 7.27 (d, *J* = 2.2 Hz, 1H), 6.99 (dd, *J* = 8.0, 2.2 Hz, 1H), 6.52 (d, *J* = 8.0 Hz, 1H), 1.80 – 1.67 (m, 2H), 1.67 – 1.58 (m, 2H), 1.37 (s, 6H), 1.29 (s, 9H), 1.10 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 143.8, 143.3, 139.3, 123.6, 123.0, 122.5, 52.6, 38.4, 38.3, 36.8, 34.4, 31.8, 29.6. HRMS (ESI) calcd. for C₁₈H₃₀N [M+H]⁺ *m/z* 260.2378, found 260.2388.


2,2,5,5-tetramethyl-7-phenyl-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepine (2e)



Prepared according to general procedure (D) using **1e** to provide the title compound **2e** as a colorless oil (71.1 mg, 0.26 mmol, 85%). IR (neat, cm⁻¹) 3342, 2955, 2909, 1600, 1475, 1449, 1437, 1385, 1361, 1277, 1242, 1195, 1177, 1163, 1146, 1104, 1086, 1052, 1018, 944, 889, 826, 806, 754, 696, 609, 585, 554, 511, 495. ¹H NMR (400 MHz, CDCl₃) δ 7.56 (d, *J* = 7.6 Hz, 2H), 7.50 (s, 1H), 7.39 (t, *J* = 7.6 Hz, 2H), 7.25 (dd, *J* = 15.3, 7.2 Hz, 2H), 6.66 (d, *J* = 7.9 Hz, 1H),


2.78 (s, 1H), 1.86 - 1.71 (m, 2H), 1.71 - 1.62 (m, 2H), 1.41 (s, 6H), 1.13 (s, 6H); 13 C NMR (101 MHz, CDCl₃) δ 145.6, 141.8, 140.2, 134.2, 128.7, 126.8, 126.4, 125.7, 125.0, 123.5, 52.9, 38.3, 38.1, 36.7, 29.3. HRMS (ESI) calcd. for C₂₀H₂₆N [M+H]⁺ *m/z* 280.2065, found 280.2064.

7-fluoro-2,2,5,5-tetramethyl-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepine (2g)




Prepared according to general procedure (D) using **1g** to provide the title compound **2g** as a yellow oil (45.7 mg, 0.21 mmol, 69%). IR (neat, cm⁻¹) 2959, 2927, 2857, 1726, 1592, 1509, 1481, 1468, 1444, 1384, 1364, 1267, 1200, 1175, 1103, 1019, 932, 909, 872, 809. ¹H NMR (400 MHz, CDCl₃) δ 6.96 (d, J = 11.5 Hz, 1H), 6.68 (t, J = 6.9 Hz, 1H), 6.57 – 6.48 (m, 1H), 1.80 – 1.67 (m, 2H), 1.67 – 1.58 (m, 2H), 1.35 (s, 6H), 1.09 (s, 6H).; ¹³C NMR (101 MHz, CDCl₃) δ 158.35 (d, J = 237.2 Hz), 142.02 (d, J = 6.1 Hz), 141.91 (d, J = 2.0 Hz), 123.53 (d, J = 7.9 Hz), 113.43 (d, J = 23.1 Hz), 112.25 (d, J = 21.7 Hz), 52.4, 38.1, 36.2, 28.7. HRMS (ESI) calcd. for C₁₄H₂₁NF [M+H]⁺ *m/z* 222.1658, found 222.1666.

7-chloro-2,2,5,5-tetramethyl-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepine (2h)



Prepared according to general procedure (D) using **1h** to provide the title compound **2h** as a colorless oil (64.7 mg, 0.27 mmol, 91%). IR (neat, cm⁻¹) 3351, 2958, 2915, 1593, 1496, 1477, 1439, 1391, 1362, 1277, 1236, 1194, 1177, 1163, 1138, 1120, 1096, 1084, 1066, 1020, 977, 957, 944, 877, 862, 819, 805, 765, 744, 730, 683, 646, 588, 549, 517, 504. ¹H NMR (400 MHz, CDCl₃) δ 7.20 (d, *J* = 2.4 Hz, 1H), 6.95 (dd, *J* = 8.2, 2.4 Hz, 1H), 6.53 (d, *J* = 8.2 Hz, 1H), 3.03 (s, 1H), 1.82 – 1.67 (m, 2H), 1.67 – 1.57 (m, 2H), 1.34 (s, 6H), 1.10 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 144.8, 141.8, 126.8, 126.4, 126.1, 124.1, 52.7, 38.3, 38.0, 36.3, 29.6. HRMS (ESI) calcd. for C₁₄H₂₁NCl [M+H]⁺ *m/z* 238.1363, found 238.1365.


2,2,5,5,8-pentamethyl-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepine (2i)



Prepared according to general procedure (D) using **1i** to provide the title compound **2i** as a colorless oil (43.0 mg, 0.20 mmol, 66%). IR (neat, cm⁻¹) 2957, 2924, 2855, 1729, 1612, 1509, 1443, 1380, 1363, 1256, 1222, 1199, 1161, 1079, 1019, 953, 859, 803, 733, 695, 627. ¹H NMR (400 MHz, CDCl₃) δ 7.14 (d, *J* = 7.9 Hz, 1H), 6.70 (d, *J* = 7.9 Hz, 1H), 6.43 (s, 1H), 2.23 (s,


3H), 1.72 (m, 2H), 1.82 – 1.67 (m, 2H), 1.67 – 1.57 (s, 6H), 1.10 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 145.9, 137.1, 136.0, 126.6, 123.8, 122.2, 52.7, 38.2, 37.8, 36.8, 29.6, 20.7. HRMS (ESI) calcd. for C₁₅H₂₄N [M+H]⁺ *m/z* 218.1909, found 218.1913.

8-chloro-2,2,5,5-tetramethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepine (2j)




Prepared according to general procedure (D) (but with 140 °C for 25 h.) using **1j** to provide the title compound **2j** as a colorless oil (47.6 mg, 0.20 mmol, 67%). IR (neat, cm⁻¹) 2957, 2923, 2865, 1590, 1573, 1505, 1475, 1441, 1389, 1362, 1290, 1234, 1196, 1162, 1136, 1115, 1101, 1074, 1020, 969, 950, 933, 921, 879, 851, 802, 766, 727, 685, 625, 597, 577, 514. ¹H NMR (400 MHz, CDCl₃) δ 7.16 (d, *J* = 8.4 Hz, 1H), 6.84 (dd, *J* = 8.4, 2.2 Hz, 1H), 6.62 (d, *J* = 2.2 Hz, 1H), 3.07 (s, 1H), 1.81 – 1.67 (m, 2H), 1.67 – 1.57 (m, 2H), 1.33 (s, 6H), 1.11 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 147.5, 138.6, 131.3, 127.9, 122.4, 121.2, 53.0, 38.0, 36.4, 29.2. HRMS (ESI) calcd. for C₁₄H₂₁NCl [M+H]⁺ *m/z* 238.1363, found 238.1373.

2,2,5,5-tetramethyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepine (2k)



Prepared according to general procedure (D) (but with 140 °C for 35 h.) using **1k** to provide the title compound **2k** as a yellow oil (46.3 mg, 0.17 mmol, 57%). IR (neat, cm⁻¹) 2961, 2923, 1614, 1582, 1477, 1443, 1406, 1386, 1365, 1332, 1301, 1269, 1235, 1163, 1139, 1118, 1098, 1069, 1020, 972, 953, 923, 869, 820, 807, 703, 686, 587, 512. ¹H NMR (400 MHz, CDCl₃) δ 7.35 (d, *J* = 8.2 Hz, 1H), 7.15 – 7.07 (m, 1H), 6.87 – 6.83 (m, 1H), 3.23 (s, 1H), 1.85 – 1.67 (m, 2H), 1.67 – 1.59 (m, 2H), 1.37 (s, 6H), 1.12 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 146.6, 143.8, 128.7 (q, *J* = 32.1 Hz), 127.2, 124.4 (q, *J* = 271.8 Hz), 119.2 (q, *J* = 3.6 Hz), 118.0 (q, *J* = 3.8 Hz), 53.0, 38.5, 37.9, 36.1, 29.3. HRMS (ESI) calcd. for C₁₅H₂₁NF₃ [M+H]⁺ *m*/*z* 272.1626, found 272.1632.


2,2,5,5-tetramethyl-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepine-8-carbonitrile (2l)



Prepared according to general procedure (D) (but with 140 °C for 45 h.) using **11** to provide the title compound **21** as a white solid (11.4 mg, 0.05 mmol, 33%). m.p.: 115 - 117 °C. IR (neat, cm⁻¹) 3335, 2970, 2913, 2227, 1603, 1566, 1531, 1482, 1468, 1449, 1395, 1383, 1365, 1299,


1271, 1238, 1201, 1193, 1160, 1143, 1103, 1076, 1021, 997, 956, 936, 891, 869, 811, 794, 763, 741, 707, 650, 614, 556, 516, 491. ¹H NMR (400 MHz, CDCl₃) δ 7.32 (d, *J* = 8.1 Hz, 1H), 7.15 (d, *J* = 8.0 Hz, 1H), 6.88 (s, 1H), 3.22 (s, 1H), 1.82 – 1.69 (m, 2H), 1.69 – 1.61 (m, 2H), 1.35 (s, 6H), 1.11 (s, 6H).; ¹³C NMR (101 MHz, CDCl₃) δ 147.0, 145.7, 127.6, 125.6, 125.2, 119.3, 110.1, 53.1, 38.9, 37.7, 35.9, 29.3. HRMS (ESI) calcd. for C₁₅H₂₁N₂ [M+H]⁺ *m*/*z* 229.1705, found 229.1697.

2,2,5,5-tetramethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepine-6-carbonitrile (2l')




Prepared according to general procedure (D) (but with 140 °C for 45 h.) using **11** to provide the title compound **21'** as a white solid (8.5 mg, 0.03 mmol, 15%). m.p.: 104 – 106 °C. IR (neat, cm⁻¹) 3346, 3325, 2952, 2921, 2868, 2218, 1726, 1600, 1574, 1514, 1477, 1447, 1414, 1382, 1362, 1284, 1237, 1182, 1156, 1122, 1108, 1075, 1055, 1022, 999, 956, 936, 875, 840, 810, 749, 725, 703, 644, 622, 587, 520, 481, 464, 438. ¹H NMR (400 MHz, CDCl₃) δ 7.29 (d, *J* = 7.6 Hz, 1H), 7.02 (t, *J* = 7.6 Hz, 1H), 6.78 (d, *J* = 7.9 Hz, 1H), 2.84 (s, 1H), 1.78 – 1.51 (m, 10H), 1.14 (s, 6H).; ¹³C NMR (101 MHz, CDCl₃) δ 145.9, 142.9, 130.9, 128.8, 126.8, 121.6, 113.0, 55.6, 40.6, 38.4, 35.1, 30.2. HRMS (ESI) calcd. for C₁₅H₂₁N₂ [M+H]⁺ *m*/z 229.1705, found 229.1697.

8-methoxy-2,2,5,5-tetramethyl-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepine (2m) + 6-methoxy-2,2,5,5-tetramethyl-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepine (2m')




Prepared according to general procedure (D) using **1m** to provide the title compound **2m** and **2m'** as a mixture (**2m**:**2m'**=1.04:1, colorless oil, 44.0 mg, 0.19 mmol, 63%). IR (neat, cm⁻¹) 3346, 2953, 2923, 2865, 1609, 1582, 1502, 1464, 1438, 1382, 1361, 1316, 1289, 1256, 1207, 1161, 1130, 1085, 1064, 1043, 1021, 993, 952, 925, 847, 794, 758, 727, 699, 638. ¹H NMR (400 MHz, CDCl₃) δ 7.17 (d, *J* = 8.6 Hz, 1H), 6.94 (t, *J* = 8.0 Hz, 1.04H), 6.55 (d, *J* = 8.1 Hz, 1.04H), 6.44 (d, *J* = 8.6 Hz, 1H), 6.24 (d, *J* = 7.8 Hz, 1.04H), 6.19 (d, *J* = 1.9 Hz, 1H), 3.79 (s, 3.12H), 3.76 (s, 3H), 1.93 – 1.51 (m, 8.16H), 1.42 (s, 6.24H), 1.35 (s, 6.24H), 1.15 (s, 6H), 1.12 (s, 6H),; ¹³C NMR (101 MHz, CDCl₃) δ 160.7, 158.0, 147.3, 145.4, 132.8, 127.6, 127.4, 126.5, 117.6, 108.9, 106.7, 105.7, 55.7, 55.4, 55.2, 52.9, 40.0, 39.7, 38.2, 37.5, 36.9, 34.6, 30.7, 29.4. HRMS (ESI) calcd. for C₁₅H₂₄NO [M+H]⁺ *m/z* 234.1858, found 234.1861.

2,2,5,5,9-pentamethyl-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepine (2n)




Prepared according to general procedure (D) (but for 35 h.) using **1n** to provide the title compound **2n** as a colorless oil (35.8 mg, 0.17 mmol, 55%). IR (neat, cm⁻¹) 3401, 2956, 2927, 1590, 1471, 1438, 1422, 1385, 1360, 1260, 1247, 1217, 1171, 1161, 1131, 1113, 1090, 1064, 1029, 959, 941, 898, 789, 758, 732, 691, 634, 556. ¹H NMR (400 MHz, CDCl₃) δ 7.19 (d, *J* = 7.9 Hz, 1H), 7.00 (d, *J* = 7.3 Hz, 1H), 6.81 (t, *J* = 7.6 Hz, 1H), 3.26 (s, 1H), 2.23 (s, 3H), 1.85 – 1.70 (m, 2H), 1.70 – 1.61 (m, 2H), 1.40 (s, 6H), 1.14 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 144.7, 140.3, 128.4, 128.0, 124.8, 120.7, 52.9, 38.6, 38.3, 36.6, 29.0, 19.3. HRMS (ESI) calcd. for C₁₅H₂₄N [M+H]⁺ *m*/z 218.1909, found 218.1913.

2-ethyl-2,5,5-trimethyl-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepine (20)




Prepared according to general procedure (D) using **10** to provide the title compound **20** as a colorless oil (55.3 mg, 0.26 mmol, 85%). IR (neat, cm⁻¹) 2961, 2928, 1599, 1581, 1470, 1441, 1384, 1358, 1293, 1259, 1237, 1171, 1129, 1089, 1053, 998, 921, 748, 695, 669, 605, 544, 504. ¹H NMR (400 MHz, CDCl₃) δ 7.27 (dd, J = 7.7, 1.4 Hz, 1H), 7.01 (td, J = 7.4, 1.4 Hz, 1H), 6.89 (td, J = 7.5, 1.2 Hz, 1H), 6.62 (dd, J = 7.7, 1.2 Hz, 1H), 2.87 (s, 1H), 1.87 – 1.69 (m, 2H), 1.69 – 1.60 (m, 2H), 1.48 – 1.39 (m, 2H), 1.37 (d, J = 4.9 Hz, 6H), 1.04 (s, 3H), 0.88 (t, J = 7.4 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 145.8, 140.0, 126.6, 126.4, 123.2, 121.3, 55.0, 38.2, 36.2, 35.8, 34.1, 29.0, 26.5, 8.4. HRMS (ESI) calcd. for C₁₅H₂₄N [M+H]⁺ *m/z* 218.1909, found 218.1915.

2,5,5-trimethyl-2-propyl-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepine (2p)




Prepared according to general procedure (D) (but for 35 h.) using **1p** to provide the title compound **2p** as a colorless oil (56.1 mg, 0.24 mmol, 81%). IR (neat, cm⁻¹) 2956, 2929, 2871, 1599, 1581, 1470, 1442, 1376, 1358, 1293, 1237, 1170, 1130, 1053, 949, 919, 850, 749, 700, 673, 505. ¹H NMR (400 MHz, CDCl₃) δ 7.28 (d, *J* = 7.6 Hz, 1H), 7.02 (t, *J* = 7.0 Hz, 1H), 6.90 (t, *J* = 7.3 Hz, 1H), 6.62 (d, *J* = 7.5 Hz, 1H), 3.07 (s, 1H), 1.85 – 1.60 (m, 4H), 1.50 – 1.20 (m, 10H), 1.06 (s, 3H), 0.95 – 0.80 (m, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 145.8, 140.0, 126.6, 126.4, 123.1, 121.3, 55.0, 44.0, 38.2, 36.2, 36.1, 29.0, 27.0, 17.3, 14.9. HRMS (ESI) calcd. for C₁₆H₂₆N [M+H]⁺ *m*/z 232.2065, found 232.2074.




Prepared according to general procedure (D) using **1q** to provide the title compound **2q** as a colorless oil (46.3 mg, 0.19 mmol, 63%). IR (neat, cm⁻¹) 2955, 2928, 2859, 1599, 1581, 1469, 1442, 1375, 1358, 1294, 1268, 1236, 1169, 1130, 1088, 1053, 928, 851, 749, 699, 673, 505. ¹H NMR (400 MHz, CDCl₃) δ 7.26 (d, J = 7.7 Hz, 1H), 7.00 (t, J = 7.4 Hz, 1H), 6.88 (t, J = 7.5 Hz, 1H), 6.61 (d, J = 7.6 Hz, 1H), 2.94 (s, 1H), 1.87 – 1.69 (m, 2H), 1.69 – 1.59 (m, 2H), 1.41 – 1.21 (m, 12H), 1.04 (s, 3H), 0.88 (t, J = 6.7 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 145.8, 140.0, 126.6, 126.4, 123.2, 121.3, 54.9, 38.2, 36.2, 36.2, 29.3, 26.3, 25.9, 23.5, 14.3. HRMS (ESI) calcd. for C₁₇H₂₈N [M+H]⁺ *m/z* 246.2222, found 246.2224.

2-isopropyl-2,5,5-trimethyl-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepine (2r)



Prepared according to general procedure (D) (but with 140 °C for 35 h.) using **1r** to provide the title compound **2r** as a colorless oil (46.4 mg, 0.20 mmol, 67%). IR (neat, cm⁻¹) 2958, 1598, 1580, 1469, 1442, 1388, 1371, 1358, 1294, 1262, 1238, 1130, 1102, 1090, 1053, 949, 923, 852, 745, 690, 661, 601, 550, 531, 508. ¹H NMR (400 MHz, CDCl₃) δ 7.28 (dd, *J* = 7.8, 1.2 Hz, 1H), 7.02 (td, *J* = 7.5, 1.3 Hz, 1H), 6.92 – 6.85 (m, 1H), 6.66 – 6.59 (m, 1H), 3.26 (s, 1H), 1.90 – 1.79 (m, 1H), 1.78 – 1.58 (m, 4H), 1.39 (s, 3H), 1.34 (s, 3H), 0.99 (s, 3H), 0.89 (d, *J* = 6.5 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 145.5, 139.9, 126.7, 126.4, 123.2, 121.1, 57.5, 38.4, 35.8, 33.6, 29.9, 22.6, 17.8, 16.9. HRMS (ESI) calcd. for C₁₆H₂₆N [M+H]⁺ *m*/*z* 232.2065, found 232.2070.


2-isopentyl-2,5,5-trimethyl-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepine (2s)



Prepared according to general procedure (D) (but for 35 h.) using **1s** to provide the title compound **2s** as a colorless oil (59.8 mg, 0.23 mmol, 77%). IR (neat, cm⁻¹) 2953, 2928, 2868, 1599, 1581, 1469, 1442, 1384, 1294, 1270, 1235, 1169, 1132, 1089, 1053, 948, 927, 851, 748, 699, 673, 504. ¹H NMR (400 MHz, CDCl₃) δ 7.27 (dd, J = 7.6, 1.4 Hz, 1H), 7.00 (td, J = 7.5, 1.4 Hz, 1H), 6.89 (td, J = 7.7, 1.2 Hz, 1H), 6.62 (dd, J = 7.6, 1.1 Hz, 1H), 3.08 (s, 1H), 1.88 – 1.70 (m, 2H), 1.70 – 1.61 (m, 2H), 1.47 – 1.31 (m, 9H), 1.27 – 1.15 (m, 3H), 1.04 (s, 3H), 0.91

-0.79 (m, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 145.7, 140.0, 126.6, 126.4, 123.2, 121.3, 54.9, 38.2, 36.3, 36.2, 33.0, 29.3, 28.7, 26.7, 22.9, 22.8. HRMS (ESI) calcd. for C₁₈H₃₀N [M+H]⁺ *m*/*z* 260.2378, found 260.2381.

5,5-dimethyl-1,3,4,5-tetrahydrospiro[benzo[b]azepine-2,1'-cyclohexane] (2t)




Prepared according to general procedure (D) (but for 35 h.) using **1t** to provide the title compound **2t** as a colorless oil (60.5 mg, 0.25 mmol, 83%). IR (neat, cm⁻¹) 2923, 2850, 1598, 1581, 1470, 1460, 1444, 1384, 1358, 1296, 1286, 1236, 1171, 1145, 1050, 992, 847, 748, 720, 687, 666, 506. ¹H NMR (400 MHz, CDCl₃) δ 7.31 – 7.24 (m, 1H), 7.02 (td, *J* = 7.5, 1.4 Hz, 1H), 6.89 (td, *J* = 7.7, 1.2 Hz, 1H), 6.73 – 6.67 (m, 1H), 3.45 (s, 1H), 1.77 – 1.69 (m, 2H), 1.69 – 1.61 (m, 2H), 1.61 – 1.41 (m, 8H), 1.38 – 1.28 (m, 8H); ¹³C NMR (101 MHz, CDCl₃) δ 145.1, 140.2, 126.6, 126.3, 123.2, 121.3, 53.6, 38.2, 37.4, 36.9, 35.6, 29.9, 26.1, 22.1. HRMS (ESI) calcd. for C₁₇H₂₆N [M+H]⁺ *m/z* 244.2065, found 244.2065.

2,2,5-trimethyl-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepine (2u)



Prepared according to general procedure (D) (but with DCE/Cy-H=1/1 as solvent.) using **1u** to provide the title compound **2u** as a colorless oil (22.7 mg, 0.12 mmol, 40%). IR (neat, cm⁻¹) 2959, 2922, 2852, 1462, 1377, 1259, 1086, 1015, 794, 701. ¹H NMR (400 MHz, CDCl₃) δ 7.11 (d, *J* = 7.4 Hz, 1H), 7.01 (t, *J* = 7.2 Hz, 1H), 6.90 (t, *J* = 7.3 Hz, 1H), 6.65 (d, *J* = 7.5 Hz, 1H), 3.04 – 2.90 (m, 1H), 2.59 (s, 1H), 1.86 – 1.67 (m, 2H), 1.62 – 1.40 (m, 2H), 1.33 (d, *J* = 7.1 Hz, 3H), 1.18 (s, 3H), 1.08 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 146.1, 138.0, 127.2, 126.3, 121.8, 121.6, 52.6, 39.6, 37.1, 30.2, 30.0, 29.7, 19.4. HRMS (ESI) calcd. for C₁₃H₂₀N [M+H]⁺ *m/z* 190.1596, found 190.1600.

2,2,5,5-tetramethyl-11,11-diphenyl-1,2,3,4,5,11-hexahydrofluoreno[2,3-*b*]azepine (2ab)



Prepared according to general procedure (D) using **1ab** to provide the title compound **2ab** as a white solid (113.0 mg, 0.26 mmol, 85%). m.p.: 175 – 177 °C. IR (neat, cm⁻¹) 3415, 2957, 2861, 1611, 1514, 1490, 1447, 1413, 1383, 1352, 1322, 1291, 1268, 1234, 1217, 1188, 1161, 1117,

1099, 1079, 1030, 851, 813, 781, 757, 743, 726, 697, 635, 620, 599, 515.

¹H NMR (400 MHz, CDCl₃) δ 7.65 (d, *J* = 8.6 Hz, 2H), 7.33 (d, *J* = 7.5 Hz, 1H), 7.25 (t, *J* = 7.4 Hz, 1H), 7.22 – 7.09 (m, 11H), 6.65 (s, 1H), 3.04 (s, 1H), 1.83 – 1.55 (m, 2H), 1.44 (s, 6H), 1.06 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 150.8, 149.5, 146.5, 146.4, 141.0, 139.8, 133.7, 128.3, 128.2, 127.4, 126.5, 126.3, 126.1, 120.9, 119.1, 118.1, 65.1, 52.8, 38.2, 36.7, 29.2.

¹H NMR (400 MHz, DMSO- d_6) δ 7.77 (d, J = 7.5 Hz, 1H), 7.67 (s, 1H), 7.31 (t, J = 7.9 Hz, 2H), 7.28 – 7.14 (m, 7H), 7.10 (d, J = 7.0 Hz, 4H), 7.00 (s, 1H), 4.43 (s, 1H), 1.79 – 1.51 (m, 4H), 1.38 (s, 6H), 1.04 (s, 6H); ¹³C NMR (101 MHz, DMSO- d_6) δ 150.0, 148.6, 147.3, 146.1, 140.6, 138.9, 132.1, 128.1, 127.7, 127.4, 126.4, 125.9, 125.8, 120.5, 119.2, 117.8, 64.3, 52.2, 37.8, 36.1, 28.7.

To verify the definite configuration of the products, the NMR analysis at 353 K and X-ray crystallographic analysis of 2z were conducted as a pilot example to other products 2.

¹H NMR (400 MHz, DMSO- d_6 , 353 K) δ 7.75 (dd, J = 7.3, 1.1 Hz, 1H), 7.68 (s, 1H), 7.31 (t, J = 7.5 Hz, 2H), 7.27 – 7.16 (m, 7H), 7.16 – 7.12 (m, 4H), 6.98 (s, 1H), 4.17 (s, 1H), 1.68 (s, 4H), 1.42 (s, 6H), 1.07 (s, 6H); ¹³C NMR (101 MHz, DMSO- d_6 , 353 K) δ 149.8, 148.5, 146.5, 145.6, 140.3, 138.8, 132.0, 127.5, 127.3, 126.9, 125.8, 125.4, 120.3, 118.6, 117.3, 64.1, 52.0, 37.5, 35.9, 28.4, 28.1.


HRMS (ESI) calcd. for $C_{33}H_{34}N [M+H]^+ m/z 444.2691$, found 444.2703.

X-ray crystallographic structure of 2z.


The configuration of 2z was confirmed by X-ray crystallographic analysis.

Table 1 Crystal data and structure refinement for wr-7.					
wr-7					
$C_{33}H_{33}N$					
443.60					
291(2)					
triclinic					
P-1					
8.9337(2)					
10.9430(4)					
13.0698(4)					
92.791(3)					
97.221(2)					
94.987(2)					
1260.49(7)					
2					
1.169					
0.502					
476.0					
$0.240 \times 0.220 \times 0.210$					
$CuK\alpha$ ($\lambda = 1.54184$)					

 2Θ range for data collection/° 6.83 to 142.468 Index ranges $-10 \le h \le 6, -12 \le k \le 13, -15 \le l \le 15$ Reflections collected 8360 Independent reflections 4740 [$R_{int} = 0.0195$, $R_{sigma} = 0.0263$] Data/restraints/parameters 4740/1/316 Goodness-of-fit on F² 1.052 Final R indexes $[I \ge 2\sigma(I)]$ $R_1 = 0.0473, wR_2 = 0.1308$ Final R indexes [all data] $R_1 = 0.0529, wR_2 = 0.1369$ Largest diff. peak/hole / e Å⁻³ 0.51/-0.19




Single crystal of 2z [C₃₃H₃₃N] was obtained from acetone. CCDC 1562122 contains the supplementary crystallographic data which can be obtained free of charge from The Cambridge Crystallographic Data Centere via <u>www.ccdc.cam.ac.uk/data_request/cif</u>.




Genaral procedure (E) for the novel and facile synthesis of 1-benzazepines via coppercatalyzed oxidative $C(sp^3)$ -H/C(sp²)-H cross-coupling. To an oven-dried 35 mL screw-cap sealed tube equipped with a magnetic stir bar was added Cu(OAc)2 (20 mol%), Ag2CO3 (1.5 equiv), substrate 1 (0.3 mmol, 1.0 equiv) and 1,2-dichloroethane (6.0 mL) at air atmosphere. The vessel was then sealed with a Teflon screw-cap, stirred vigorously at rt for 5 min, and placed into a preheated oil bath at 125 °C for 8 h. After completion, the reaction mixture was allowed to cool to room temperature, and was directly filtered through a short pad of silica gel washed with EtOAc. The filtrate was concentrated under vacuum and purified by column chromatography on silica gel to obtain the corresponding product 2.

2,2,5,5-tetramethyl-2,3,4,5-tetrahydro-1*H*-naphtho[1,2-*b*]azepine (2f)




Prepared according to general procedure (E) (but with 20 h) using **1f** to provide the title compound **2f** as a yellow oil (45.7 mg, 0.21 mmol, 69%). IR (neat, cm⁻¹) 3408, 2956, 2923, 1566, 1513, 1479, 1468, 1444, 1378, 1361, 1438, 1294, 1270, 1233, 1208, 1170, 1147, 1135, 1081, 1031, 935, 913, 891, 851, 807, 785, 736, 683, 658, 635, 597, 582. ¹H NMR (400 MHz, CDCl₃) δ 7.90 (d, *J* = 8.5 Hz, 1H), 7.79 (d, *J* = 7.9 Hz, 1H), 7.54 (d, *J* = 8.7 Hz, 1H), 7.45 (d, *J* = 8.8 Hz, 1H), 7.40 (t, *J* = 7.2 Hz, 1H), 3.99 (s, 1H), 1.71 – 1.71 (m, 4H), 1.48 (s, 6H), 1.22 (s, 6H).; ¹³C NMR (101 MHz, CDCl₃) δ 140.4, 136.1, 133.2, 129.0, 128.5, 125.8, 125.4, 124.8, 121.4, 121.2, 53.1, 38.6, 38.4, 36.7, 29.2. HRMS (ESI) calcd. for C₁₄H₂₁NF [M+H]⁺ *m*/z 254.1909, found 254.1902.

10,10-dimethyl-10,11-dihydro-5*H*-dibenzo[*b*,*f*]azepine (2v)



Prepared according to general procedure (E) using **1v** to provide the title compound **2v** as a colorless oil (46.8 mg, 0.21 mmol, 70%). IR (neat, cm⁻¹) 3389, 2957, 2924, 1612, 1590, 1526, 1481, 1444, 1385, 1363, 1338, 1273, 1247, 1213, 1155, 1120, 1086, 1053, 968, 933, 898, 846, 739, 689, 660, 622, 607, 569, 524, 495, 449. ¹H NMR (400 MHz, CDCl₃) δ 7.35 (dd, *J* = 7.9, 1.3 Hz, 1H), 7.15 – 7.03 (m, 3H), 6.88 – 6.79 (m, 2H), 6.79 – 6.71 (m, 2H), 5.93 (s, 1H), 2.98 (s, 2H), 1.34 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 143.2, 141.8, 135.3, 131.4, 128.4, 128.0, 127.0, 126.8, 120.3, 119.6, 119.3, 117.3, 47.9, 37.9, 31.5. HRMS (ESI) calcd. for C₁₆H₁₈N [M+H]⁺ *m/z* 224.1439, found 224.1445.


2,10,10-trimethyl-10,11-dihydro-5*H*-dibenzo[*b*,*f*]azepine (2w)



Prepared according to general procedure (E) (but for 6 h.) using **1w** to provide the title compound **2w** as a colorless oil (51.2 mg, 0.22 mmol, 72%). IR (neat, cm⁻¹) 3379, 2958, 2923, 1614, 1594, 1509, 1487, 1435, 1383, 1362, 1337, 1277, 1258, 1209, 1166, 1156, 1132, 1115, 1087, 1054, 979, 933, 907, 887, 813, 748, 653, 630, 564, 524, 504, 471, 451. ¹H NMR (400 MHz, CDCl₃) δ 7.35 (dd, J = 7.9, 1.2 Hz, 1H), 7.09 – 7.02 (m, 1H), 6.91 (d, J = 7.5 Hz, 2H), 6.84 – 6.78 (m, 1H), 6.75 – 6.70 (m, 1H), 6.67 (d, J = 7.7 Hz, 1H), 5.83 (s, 1H), 2.95 (s, 2H), 2.29 (s, 3H), 1.34 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 142.1, 140.9, 135.1, 131.9, 129.6, 128.5, 128.1, 127.5, 126.8, 119.3, 119.2, 117.3, 47.7, 37.8, 31.6, 20.7. HRMS (ESI) calcd. for


 $C_{17}H_{20}N [M+H]^+ m/z 238.1596$, found 238.1599.

2-chloro-10,10-dimethyl-10,11-dihydro-5*H*-dibenzo[*b*,*f*]azepine (2x)




Prepared according to general procedure (E) using **1x** to provide the title compound **2x** as a colorless oil (59.4 mg, 0.23 mmol, 77%). IR (neat, cm⁻¹) 3381, 2957, 2923, 1612, 1593, 1508, 1486, 1435, 1383, 1362, 1339, 1276, 1258, 1208, 1165, 1131, 1115, 1087, 1053, 886, 809, 748, 693, 629, 563, 523, 503, 481, 472, 451. ¹H NMR (400 MHz, CDCl₃) δ 7.35 (dd, *J* = 7.9, 1.2 Hz, 1H), 7.11 – 7.02 (m, 3H), 6.87 – 6.81 (m, 1H), 6.75 – 6.71 (m, 1H), 6.71 – 6.65 (m, 1H), 5.91 (s, 1H), 2.93 (s, 2H), 1.33 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 141.8, 141.3, 135.2, 130.8, 129.6, 128.3, 126.9, 126.8, 124.9, 119.9, 119.4, 118.5, 47.6, 37.8, 31.4. HRMS (ESI) calcd. for C₁₆H₁₇NCl [M+H]⁺ *m/z* 258.1050, found 258.1051.

3-chloro-10,10-dimethyl-10,11-dihydro-5*H*-dibenzo[*b*,*f*]azepine (2y)



Prepared according to general procedure (E) (but for 6 h.) using **1y** to provide the title compound **2y** as a colorless oil (54.0 mg, 0.21 mmol, 70%). IR (neat, cm⁻¹) 3390, 2958, 2924, 1607, 1581, 1527, 1481, 1397, 1384, 1364, 1342, 1331, 1263, 1197, 1086, 1052, 975, 935, 839, 790, 746, 696, 665, 609, 584, 497, 480, 457. ¹H NMR (400 MHz, CDCl₃) δ 7.35 (d, *J* = 7.9 Hz, 1H), 7.08 (t, *J* = 7.5 Hz, 1H), 6.98 (d, *J* = 7.9 Hz, 1H), 6.85 (t, *J* = 7.5 Hz, 1H), 6.79 (d, *J* = 7.9 Hz, 1H), 6.78 – 6.76 (m, 1H), 6.72 (d, *J* = 8.0 Hz, 1H), 5.94 (s, 1H), 2.92 (s, 2H), 1.32 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 144.0, 141.1, 135.5, 132.5, 132.2, 128.1, 127.0, 126.1, 120.1, 120.0, 119.5, 117.0, 47.5, 37.8, 31.1. HRMS (ESI) calcd. for C₁₆H₁₇NCl [M+H]⁺ *m/z* 258.1050, found 258.1051.


3-fluoro-10,10-dimethyl-10,11-dihydro-5*H*-dibenzo[*b*,*f*]azepine (2z)



Prepared according to general procedure (E) (but for 6 h.) using **1z** to provide the title compound **2z** as a colorless oil (59.3 mg, 0.25 mmol, 82%). IR (neat, cm⁻¹) 3390, 2957, 2926, 1615, 1598, 1582, 1505, 1482, 1385, 1364, 1344, 1275, 1252, 1221, 1151, 1116, 1104, 1087, 1052, 993, 935, 836, 803, 747, 694, 607. ¹H NMR (400 MHz, CDCl₃) δ 7.35 (dd, *J* = 7.9, 1.2

Hz, 1H), 7.11 – 7.04 (m, 1H), 7.03 – 6.96 (m, 1H), 6.89 – 6.81 (m, 1H), 6.76 – 6.70 (m, 1H), 6.53 (td, J = 8.3, 2.5 Hz, 1H), 6.47 (dd, J = 10.3, 2.4 Hz, 1H), 5.94 (s, 1H), 2.92 (s, 2H), 1.32 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 162.0 (d, J = 242.4 Hz), 144.1 (d, J = 9.9 Hz), 141.2, 135.5, 132.5 (d, J = 9.5 Hz), 128.2, 126.9, 123.4, 123.4, 120.1, 119.4, 106.8 (d, J = 21.0 Hz), 103.9 (d, J = 24.2 Hz), 47.3, 37.8, 31.1. HRMS (ESI) calcd. for C₁₆H₁₇NF [M+H]⁺ m/z 242.1345, found 242.1348.

10,10-dimethyl-3-(trifluoromethyl)-10,11-dihydro-5*H*-dibenzo[*b*,*f*]azepine (2aa)



Prepared according to general procedure (E) (but for 6 h.) using **1aa** to provide the title compound **2aa** as a colorless oil (72.5 mg, 0.25 mmol, 83%). IR (neat, cm⁻¹) 3394, 2962, 1591, 1541, 1510, 1485, 1410, 1388, 1322, 1243, 1160, 1114, 1074, 1052, 976, 937, 866, 846, 805, 747, 686, 657. ¹H NMR (400 MHz, CDCl₃) δ 7.36 (dd, J = 7.9, 1.2 Hz, 1H), 7.17 (d, J = 7.8 Hz, 1H), 7.13 – 7.07 (m, 1H), 7.06 (d, J = 8.0 Hz, 1H), 7.01 (s, 1H), 6.90 – 6.83 (m, 1H), 6.79 – 6.73 (m, 1H), 6.07 (s, 1H), 3.00 (s, 2H), 1.34 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 143.2, 141.0, 135.4, 131.9, 131.2, 129.5 (q, J = 32.3 Hz), 128.2, 127.1, 124.3 (q, J = 273.0 Hz), 120.3, 119.5, 116.6 (q, J = 3.8 Hz), 114.0 (q, J = 3.7 Hz), 47.9, 37.8, 31.2. HRMS (ESI) calcd. for C₁₇H₁₇NF₃ [M+H]⁺ m/z 292.1313, found 292.1317.

IV. Mechanism Details.

H N	Standard Conditions	H K
entry	Addtives	yield ^a
1	TEMPO (1.0 eq.)	0
2	TEMPO (0.5 eq.)	0
3	TEMPO (0.3 eq.)	trace
4	Galvinoxyl (1.0 eq.)	0
5	Galvinoxyl (0.5 eq.)	0
6	Galvinoxyl (0.3 eq.)	0
7	BHT (1.0 eq.)	0
8	BHT (0.5 eq.)	0
9	BHT (0.3 eq.)	trace


Table S8 | Effects of Radical Inhibitors

^aDetermined by TLC and isolating.


V. References.


[1] Barros, M. T.; Dey, S. S.; Maycock, C. D.; Rodrigues, P. Chem. Commun., 2012, 48, 10901.


[2] Tewari, A.; Hein, M.; Zapf, A.; Beller, M. Tetrahedron, 2005, 61, 9705.





VI. Spectroscopic Data (NMR Spectrum).






















210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 fl (ppm)




















































































210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 f1 (ppm)















210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 fl (ppm)









210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 r1 (ppm)

